Drug Profile

BSC 3201

Alternative Names: BSC-3201

Latest Information Update: 06 Jul 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator BiSiChem
Class Antiparkinsonians; Small molecules
Mechanism of Action Nuclear receptor subfamily 4 group A member 2 modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

27 Jun 2023 Preclinical trials in Parkinson's disease in South Korea (unspecified route) before June 2023 (BiSiChem pipeline, June 2023)
31 Oct 2018 BiSiChem enters into an collaboration agreement with Lifex Biolabs for the development of BSC 3201 (BiSiChem pipeline, June 2023)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com